Progress and predictions: AML in 2018.
Rowe, Jacob M
Progress and predictions: AML in 2018. [electronic resource] - Best practice & research. Clinical haematology 12 2018 - 337-340 p. digital
Publication Type: Journal Article; Review
1532-1924
10.1016/j.beha.2018.09.002 doi
Drug Approval
High-Throughput Nucleotide Sequencing
Humans
Isocitrate Dehydrogenase--antagonists & inhibitors
Leukemia, Myeloid, Acute--drug therapy
Neoplasm, Residual
Protein Kinase Inhibitors--therapeutic use
United States
United States Food and Drug Administration
fms-Like Tyrosine Kinase 3--antagonists & inhibitors
Progress and predictions: AML in 2018. [electronic resource] - Best practice & research. Clinical haematology 12 2018 - 337-340 p. digital
Publication Type: Journal Article; Review
1532-1924
10.1016/j.beha.2018.09.002 doi
Drug Approval
High-Throughput Nucleotide Sequencing
Humans
Isocitrate Dehydrogenase--antagonists & inhibitors
Leukemia, Myeloid, Acute--drug therapy
Neoplasm, Residual
Protein Kinase Inhibitors--therapeutic use
United States
United States Food and Drug Administration
fms-Like Tyrosine Kinase 3--antagonists & inhibitors